Dr. Mara D. Chambers, MD
Hematology & Oncology (Hematology & Oncology Physician)
740 S Limestone
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Louisville School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 162
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Louisville School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 31021 -
Internal Medicine Physician
KY license 31021 -
Medical Oncology Physician
KY license 31021
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kentucky Hospital Lexington, KY
- Pikeville Medical Center Pikeville, KY
Medical groups
- Kentucky Medical Services Foundation, Inc (967 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 162
- Services billed
- 276
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 120 | 79 |
| Established patient office or other outpatient visit, 40-54 minutes | 110 | 43 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Lexington, KY | 493 |
| Letrozole Other prescribers in Lexington, KY | 125 |
| Ibrance (palbociclib) | 31 |
| Prochlorperazine Maleate Other prescribers in Lexington, KY | 30 |
| Exemestane | 29 |
| Verzenio (abemaciclib) | 25 |
| Oxycodone Hcl Other prescribers in Lexington, KY | 24 |
| Morphine Sulfate Other prescribers in Lexington, KY | 22 |
| Ondansetron Hcl Other prescribers in Lexington, KY | 19 |
| Potassium Chloride Other prescribers in Lexington, KY | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $66.18 in total to this clinician.
| Spr Therapeutics, Inc | $66.18 |
|---|
| Food and Beverage | $66.18 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $24,299 in research payments for these studies, mostly to the institutions running them.
- Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04622319
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.